Inapill develops first-in-class, orally available small molecule therapeutics. These molecules target immunometabolism to improve treatments for inflammatory, autoimmune, and age-related diseases. Their approach involves suppressing multiple pro-inflammatory cytokines by tuning mitochondrial function in immune cells.